HALO
HealthcareHalozyme Therapeutics, Inc.
$71.20
+$0.89 (+1.27%)
Jan 5, 2026
Price History (1Y)
Analysis
Halozyme Therapeutics, Inc. is a biotechnology company that operates in the healthcare sector. The company has a significant market presence with a market capitalization of $8.37 billion and annual revenues of $1.24 billion. The company's financial health indicates robust profitability, with gross margins reaching 78.9% and operating margins standing at 61.5%. This strong performance is reflected in the net income, which amounts to $595.49 million on a trailing twelve-month basis. The company also generates significant free cash flow of $428.44 million, while maintaining a cash balance of $701.96 million against total debt of $1.54 billion. The valuation of Halozyme Therapeutics is supported by its earnings growth rate of 36.2% year-over-year, which is higher than the revenue growth rate of 22.1%. The price-to-earnings ratio stands at 14.83 on a trailing basis and 8.76 forward-looking, while the debt to equity ratio is 305.38.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $8.37B
- P/E Ratio
- 14.83
- 52-Week High
- $79.50
- 52-Week Low
- $47.50
- Avg Volume
- 2.17M
- Beta
- 0.94
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 350